Table 3.
Female-to-male ratio of the percentage reporting adverse events following the Pfizer-BioNTech COVID-19 vaccine and lasting more than 24 h, in a cross-sectional study.
| Adverse Event | First Dose | Second Dose | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male (N = 152), n (%) | Female (N = 114), n (%) |
F to M Ratio | 95% CI | p-Value | Male (N = 152), n (%) | Female (N = 114), n (%) |
F to M Ratio | 95% CI | p-Value | |
| Local | ||||||||||
| Swelling in the injection area | 29 (19.1) | 44 (38.6) | 2.02 | 1.15–2.64 | 0.0001 | 24 (15.8) | 33(28.9) | 1.83 | 0.99–2.60 | 0.008 |
| Pain in the injection area | 74 (48.7) | 80 (70.2) | 1.44 | 0.98–1.62 | 0.0001 | 49 (32.2) | 69(60.5) | 1.88 | 1.14–2.10 | 0.0001 |
| Pain all over the injected hand | 8 (5.3) | 24 (21.1) | 3.98 | 1.62–7.49 | 0.0001 | 9 (5.9) | 24(21.1) | 3.58 | 1.50–6.47 | 0.0001 |
| Rash or redness in the injection area | 2 (1.3) | 5 (4.4) | 3.38 | 0.64–16.39 | 0.123 | 1 (0.7) | 4(3.5) | 5.00 | 0.59–45.79 | 0.109 |
| Systemic | ||||||||||
| Fever | 0 (0) | 1 (0.9) | NA | NA | 0.429 | 10 (6.6) | 16(14.0) | 2.12 | 0.94–4.25 | 0.035 |
| Shivering | 3 (2.0) | 12 (10.5) | 5.25 | 1.42–17.06 | 0.003 | 11 (7.2) | 35(30.7) | 4.26 | 1.84–6.60 | 0.0001 |
| Muscle pains | 8 (5.3) | 17 (14.9) | 2.81 | 1.16–5.82 | 0.007 | 16 (10.5) | 38(33.3) | 3.17 | 1.53–4.51 | 0.0001 |
| Joint pains | 1 (0.7) | 3 (2.6) | 3.71 | 0.41–37.23 | 0.212 | 5 (3.3) | 15(13.2) | 4.00 | 1.36–9.78 | 0.003 |
| Headaches | 3 (2.0) | 18 (15.8) | 7.90 | 2.12–23.39 | 0.0001 | 11 (7.2) | 33(28.9) | 4.01 | 1.75–6.34 | 0.0001 |
| Fatigue | 9 (5.9) | 21 (18.4) | 3.12 | 1.32–5.87 | 0.0001 | 28 (18.4) | 45(39.5) | 2.15 | 1.19–2.77 | 0.0001 |
| Lack of ability to stand | 1 (0.7) | 7 (6.1) | 8.71 | 1.10–70.97 | 0.012 | 3 (2.0) | 15(13.2) | 6.60 | 1.78–20.30 | 0.0001 |
| General weakness | 2 (1.3) | 21 (18.4) | 14.15 | 2.86–50.15 | 0.0001 | 15 (9.9) | 30(26.3) | 2.66 | 1.30–4.14 | 0.0001 |
| Allergy | 0 (0) | 2 (1.8) | NA | NA | 0.183 | 1 (0.7) | 1 (0.9) | 1.29 | 0.08–21.05 | 0.674 |
| Anaphylaxis | 0 | 0 | NA | NA | NA | 0 | 0 | NA | NA | NA |
| Sensory | ||||||||||
| Paresthesia in the injected hand | 0 (0) | 8 (7.0) | NA | NA | 0.001 | 0 (0) | 6(5.5) | NA | NA | 0.006 |
| Facial paralysis | 1 (0.7) | 0 (0) | NA | NA | 0.571 | 1 (0.7) | 1 (0.9) | 1.29 | 0.08–21.05 | 0.674 |
| Facial paresthesia | 0 (0) | 2 (1.8) | NA | NA | 0.183 | 1 (0.7) | 1 (0.9) | 1.29 | 0.08–21.05 | 0.674 |
| Herpes zoster | 0 (0) | 1 (0.9) | NA | NA | 0.429 | 1 (0.7) | 0(0) | NA | NA | 0.571 |